Table 1.
Baseline characteristics of the study population.
| Pembrolizumab (n) | Nivolumab (n) | Ipilimumab (n) | Nivolumab-ipilimumab (n) | |
|---|---|---|---|---|
| Gender | ||||
| Male | 49 | 99 | 3 | 6 |
| Female | 30 | 46 | 1 | 0 |
|
| ||||
| Cancer type | ||||
| Lung | 85 | 85 | ||
| GI | 6 | 9 | ||
| Melanoma | 4 | 25 | 4 | 5 |
| Neuroendocrine | 1 | 4 | ||
| RCC | 2 | 15 | 1 | |
| Bladder | 5 | 2 | ||
| Head and neck | 8 | |||
| Laryngeal | 2 | |||
| Prostate | 1 | |||
| Hodgkin lymphoma | 1 | |||
| HCC | 1 | |||
| Mesothelioma | 2 | |||
|
| ||||
| Factors affecting calcium levels | ||||
| Metastasis to bone | 11 | 26 | ||
| Calcium supplements | 6 | 10 | 1 | |
| Vitamin D | 8 | 36 | 3 | 3 |
| Bisphosphonates | 9 | 9 | 1 | |
| History of neck radiation | 6 | |||
| History of parathyroidectomy | ||||
| >stage IIIB CKD | 2 | |||
| History of hypo/hyperparathyroidism | ||||
|
| ||||
| Lost to follow-up | ||||
| Deceased | 15 | 25 | ||
| Disease progression | 21 | 69 | ||
| Treatment completed | 4 | 10 | 1 | |
| Treatment changed | 1 | |||
| Hospice | 5 | 9 | ||
| Changed MD | 1 | 2 | ||
| No-show | 1 | |||
| Drug intolerance | 3 | 4 | ||
| Ongoing | 28 | 10 | ||
| Insurance | 2 | |||
| Lost to follow-up | 4 | |||
| Change in comorbidities | 2 | |||